Promising Results from Clinical Trial of Tesomet in Treatment of Hypothalamic Obesity
Last week, Saniona, biopharmaceutical company focused on rare diseases, announced top line results from its 24-week double blind, randomized, placebo-controlled Phase 2 trial evaluating the safety and efficacy of Tesomet in patients with hypothalamic obesity (HO).
A Webinar on Hypothalamic Obesity with Marci Serota, RDN
If you were unable to attend our Meet the Experts webinar with Marci Serota, RDN ... Read more
RAWF Offers Complimentary Copies of Hungry for Solutions to Brain Tumor Patients Suffering from Hypothalamic Obesity
Hypothalamic Obesity (HO) can be a devastating co-morbidity of brain tumors around the pituitary/hypothalamic axis. The condition can mean uncontrollable hunger and weight gain in patients due to damage to the hypothalamus which acts as the control center for our hunger and thirst. When this mechanism is damaged, the body can be tricked into starvation mode, making the patient constantly hungry and storing calories as fat.